Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:47:20.162Z.
Consensus retrieved: 2026-10-06T13:56:11.588Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:47:20.162Z.
Quote observation: 2026-10-06T17:43:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9bf447c1d5373d17b51517f64cfe8ce44e33b4ae98b3907fdc05662a19d62e0e
Forward PE Ratio (N/A) = Dated Quote Price ($1.05) / Consensus Forward EPS ($-2.49)
FORWARD PE RATIO
N/A
Metagenomi, Inc. Common Stock
Market Cap
$39.53M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $39.53M | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.11M | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.39M | N/A |
| Veru Inc. (VERU)vs › | $41.01M | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $37.45M | N/A |
| Precipio, Inc. (PRPO)vs › | $41.92M | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.09M | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.99M | N/A |
| Nephros, Inc. (NEPH)vs › | $36.26M | 21.32 |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.94M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.05, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.49 | $-2.79 – $-2.15 | 3 | n/m |
| 2027-12-31 | $-1.88 | $-2.19 – $-1.67 | 3 | n/m |
| 2028-12-31 | $-1.86 | $-2.97 – $-0.70 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
